Overview
Background
Dr Brett Hughes graduated from the University of NSW with a Bachelor of Medical Science and Bachelor of Medicine and Surgery in 1997. He completed his postgraduate training in Canberra and Brisbane and was admitted as a Fellow of the Australian College of Physicians as a Specialist Medical Oncologist in 2005.
Dr Hughes is currently a Senior Staff Specialist Medical Oncologist at the RBWH and TPCH. He is also an Associate Professor at the University of Queensland since 2015. As the previous Clinical Director of Oncology (201-2017) and current Cancer Care Services Research lead at TPCH, Dr Hughes has established both an independent TPCH Oncology unit and continuing TPCH’s reputation as a lung cancer research centre of excellence.
Dr Hughes is an active senior member of the Thoracic Oncology Group Australasia (TOGA) and the Trans Tasman Radiation Oncology Group (TROG). He is also heavily involved in many pivotal multicentre trials of cancer therapy at both TPCH and RBWH with his principal research interests in Lung cancer, Head & Neck cancer, Mesothelioma, cutaneous SCC and Thyroid cancer. He has published over 100 peer review papers. Dr Hughes is also involved in undergraduate and post graduate teaching in his fields of research interest.
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Fields of research
Works
Search Professor Brett Hughes’s works on UQ eSpace
2021
Journal Article
A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma
Lin, Charles, Ballah, Trishna, Nottage, Michelle, Hay, Karen, Chua, Benjamin, Kenny, Lizbeth, Thomas, Paul, Teng, Michele, Keller, Jacqui, Le, Trang, Edmunds, Jennifer and Hughes, Brett (2021). A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. Radiation Oncology, 16 (1) 69, 1-13. doi: 10.1186/s13014-021-01795-5
2021
Journal Article
Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study
Rischin, Danny, King, Madeleine, Kenny, Lizbeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Bressel, Mathias, Herschtal, Alan, Fisher, Richard, Fua, Tsien, Lin, Charles, Liu, Chen, Hughes, Brett G.M., McGrath, Margaret, McDowell, Lachlan and Corry, June (2021). Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study. International Journal of Radiation: Oncology - Biology - Physics, 111 (4), 876-886. doi: 10.1016/j.ijrobp.2021.04.015
2021
Journal Article
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)
Kulasinghe, Arutha, O'Leary, Connor, Monkman, James, Bharti, Vandhana, Irwin, Darryl, Dutta, Sanjay, Richard, Derek J., Hughes, Brett, Ladwa, Rahul and O'Byrne, Ken (2021). The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer, 160, 73-77. doi: 10.1016/j.lungcan.2021.08.005
2021
Journal Article
Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with Pembrolizumab in KEYNOTE-629
Hughes, Brett G. M., Mendoza, Rene Gonzalez, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Chirovsky, Diana, Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Grob, Jean-Jacques (2021). Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with Pembrolizumab in KEYNOTE-629. Dermatology and Therapy, 11 (5), 1777-1790. doi: 10.1007/s13555-021-00598-6
2021
Journal Article
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Rischin, Danny, Khushalani, Nikhil I., Schmults, Chrysalyne D., Guminski, Alexander, Chang, Anne Lynn S., Lewis, Karl D., Lim, Annette M., Hernandez-Aya, Leonel, Hughes, Brett G. M., Schadendorf, DIrk, Hauschild, Axel, Thai, Alesha A., Stankevich, Elizabeth, Booth, Jocelyn, Yoo, Suk-Young, Li, Siyu, Chen, Zhen, Okoye, Emmanuel, Chen, Chieh-I, Mastey, Vera, Sasane, Medha, Lowy, Israel, Fury, Matthew G. and Migden, Michael R. (2021). Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. Journal for ImmunoTherapy of Cancer, 9 (8) e002757, e002757. doi: 10.1136/jitc-2021-002757
2021
Journal Article
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
Hughes, B. G. M., Munoz-Couselo, E., Mortier, L., Bratland, Å., Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. and Grob, J.-J. (2021). Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Annals of Oncology, 32 (10), 1276-1285. doi: 10.1016/j.annonc.2021.07.008
2021
Conference Publication
Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629
Hughes, Brett G. M., Munoz-Couselo, Eva, Mortier, Laurent, Bratland, Ase, Gutzmer, Ralf, Roshdy, Osama, Gonzalez Mendoza, Rene, Schachter, Jacob, Arance, Ana, Grange, Florent, Meyer, Nicolas, Joshi, Abhishek, Billan, Salem, Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Grob, Jean-Jacques (2021). Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia Pa, Apr 10-May 21, 2021. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
2021
Journal Article
Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?
Ahern, Elizabeth, Solomon, Ben J, Hui, Rina, Pavlakis, Nick, O'Byrne, Ken and Hughes, Brett G M (2021). Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time?. Journal for ImmunoTherapy of Cancer, 9 (6) e002248, e002248. doi: 10.1136/jitc-2020-002248
2021
Journal Article
Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes
Reynolds, K. A., Schlessinger, D. I., Yanes, A. F., Godinez-Puig, V., Chen, B. R., Kurta, A. O., Cotseones, J. K., Chiren, S. G., Iyengar, S., Ibrahim, S. A., Kang, B. Y., Worley, B., Behshad, R., DeHoratius, D. M., Denes, P., Drucker, A. M., Dzubow, L. M., Etzkorn, J. R., Harwood, C. A., Kim, J. Y. S., Lawrence, N., Lee, E. H., Lissner, G. S., Marghoob, A. A., Guminiski, A., Matin, R. N., Mattox, A. R., Mittal, B. B., Thomas, J. R. ... Alam, M. (2021). Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes. British Journal of Dermatology, 184 (6), 1113-1122. doi: 10.1111/bjd.19693
2021
Conference Publication
KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)
Bratland, Ase, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, Gonzalez, Rene, Schachter, Jacob, Arance, Ana Maria, Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett Gordon Maxwell, Grob, Jean-Jacques, Ramakrishnan, Karthik, Zhang, Eric (Pingye), Gumuscu, Burak, Swaby, Ramona F. and Gutzmer, Ralf (2021). KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 04-08, 2021. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2021.39.15_suppl.9546
2021
Journal Article
EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non–small cell lung cancer
Leal, Jose Luis, Alexander, Marliese, Itchins, Malinda, Wright, Gavin M., Kao, Steven, Hughes, Brett G.M., Pavlakis, Nick, Clarke, Stephen, Gill, Anthony J, Ainsworth, Hannah, Solomon, Benjamin and John, Thomas (2021). EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non–small cell lung cancer. Clinical Lung Cancer, 22 (6), e859-e869. doi: 10.1016/j.cllc.2021.04.009
2021
Journal Article
Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia
Gasper, Harry, Ahern, Elizabeth, Roberts, Natasha, Chan, Bryan, Hughes, Brett, Kennedy, Glen, Wyld, David, Eastgate, Melissa and Lwin, Zarnie (2021). Semiqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia. BMJ Open, 11 (5) e044655, e044655. doi: 10.1136/bmjopen-2020-044655
2021
Journal Article
Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients
Kulasinghe, Arutha, Taheri, Touraj, O'Byrne, Ken, Hughes, Brett G. M., Kenny, Liz and Punyadeera, Chamindie (2021). Highly multiplexed digital spatial profiling of the tumor microenvironment of head and neck squamous cell carcinoma patients. Frontiers in Oncology, 10 607349, 607349. doi: 10.3389/fonc.2020.607349
2021
Journal Article
CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC
Leighl, Natasha B., Laurie, Scott A., Goss, Glenwood D., Hughes, Brett G.M., Stockler, Martin, Tsao, Ming-Sound, Hwang, David M., Joubert, Phillipe, Kulkarni, Swati, Blais, Normand, Joy, Anil A., Mates, Mihaela, Rana, Punam, Yadav, Sunil K., Underhill, Craig, Lee, Christopher, Bradbury, Penelope A., Hiltz, Andrea, Dancey, Janet, Ding, Keyue and Vera-Badillo, Francisco (2021). CCTG BR34: a randomized phase 2 trial of Durvalumab and Tremelimumab with or without platinum-based chemotherapy in patients with metastatic NSCLC. Journal of Thoracic Oncology, 17 (3), 434-445. doi: 10.1016/j.jtho.2021.10.023
2020
Journal Article
CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells
Braun, Matthias, Aguilera, Amelia Roman, Sundarrajan, Ashmitha, Corvino, Dillon, Stannard, Kimberley, Krumeich, Sophie, Das, Indrajit, Lima, Luize G., Meza Guzman, Lizeth G., Li, Kunlun, Li, Rui, Salim, Nazhifah, Jorge, Maria Villancanas, Ham, Sunyoung, Kelly, Gabrielle, Vari, Frank, Lepletier, Ailin, Raghavendra, Ashwini, Pearson, Sally, Madore, Jason, Jacquelin, Sebastien, Effern, Maike, Quine, Brodie, Koufariotis, Lambros T., Casey, Mika, Nakamura, Kyohei, Seo, Eun Y., Hölzel, Michael, Geyer, Matthias ... Bald, Tobias (2020). CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells. Immunity, 53 (4), 805-823.e15. doi: 10.1016/j.immuni.2020.09.010
2020
Journal Article
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Nowak, Anna K, Lesterhuis, W Joost, Kok, Peey-Sei, Brown, Chris, Hughes, Brett GM, Karikios, Deme J, John, Thomas, Kao, Steven C-H, Leslie, Connull, Cook, Alistair M, Pavlakis, Nick, Briscoe, Karen, O'Byrne, Kenneth J, Karapetis, Christos S, Lam, Wei-Sen, Langford, Ailsa, Yip, Sonia and Stockler, Martin R (2020). Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. The Lancet Oncology, 21 (9), 1213-1223. doi: 10.1016/S1470-2045(20)30462-9
2020
Journal Article
Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)
Grob, Jean-Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Hughes, Brett G. M. (2020). Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). Journal of Clinical Oncology, 38 (25), 2916-2925. doi: 10.1200/JCO.19.03054
2020
Conference Publication
Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer
Kulasinghe, Arutha, Kapeleris, Joanna, Kenny, Liz, Hughes, Brett, Warkiani, Majid, Vela, Ian, Thiery, Jean-Paul, O'Byrne, Ken and Punyadeera, Chamindie (2020). Abstract 3384: characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer. AACR Annual Meeting 2020, Philadelphia, PA USA, 27-28 April 2020 and 22-24 June 2020. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/1538-7445.am2020-3384
2020
Conference Publication
Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC)
O'Leary, Connor, Fletcher, James, Yuile, Alexander, Xu, Wen, Ladwa, Rahul, McGrath, Margaret, Pavlakis, Nick, Hughes, Brett, McCaffery, Elizabeth and O'Byrne, Kenneth (2020). Limited benefit of adjuvant chemotherapy in resected Epidermal Growth Factor Receptor (EGFR) positive non-small cell lung cancer (NSCLC). Medical Oncology Group of Australia Annual Scientific Meeting, Virtual, Australia, 14-21 August 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell.
2020
Journal Article
Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma
Tang, Kai D., Vasani, Sarju, Menezes, Lilian, Taheri, Touraj, Walsh, Laurence J., Hughes, Brett G.M., Frazer, Ian H., Kenny, Liz, Scheper, Gert C. and Punyadeera, Chamindie (2020). Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma. Cancer Science, 111 (10) cas.14585, 3854-3861. doi: 10.1111/cas.14585
Supervision
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
The changing face of head and neck cancer: addressing and advancing best-practice nutritional care to improve outcomes for patients with human papillomavirus-associated disease
Associate Advisor
-
Doctor Philosophy
Developing predictive biomarkers for immunotherapy using deep spatial profiling
Associate Advisor
Other advisors: Associate Professor Arutha Kulasinghe
Completed supervision
-
2025
Doctor Philosophy
The investigation of the tumour microenvironment in head and neck squamous cell carcinoma to identify predictive biomarkers of response to immunotherapy
Associate Advisor
Other advisors: Dr Quan Nguyen, Associate Professor Arutha Kulasinghe
Media
Enquiries
For media enquiries about Associate Professor Brett Hughes's areas of expertise, story ideas and help finding experts, contact our Media team: